ReviewNature reviews. Microbiology2026
Phage therapy: from basic biology to clinical application.
Review in Nature reviews. Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bacteriophages have been applied therapeutically for more than a century for the management of bacterial infections in humans. Although their potential as a safe alternative or adjunct to antibiotics is well established, clinical success is difficult to predict from in vitro testing. There is currently no consensus on the optimal way to use them, nor are there any simple extrapolations from the use paradigms of conventional antibiotics. A rational approach to phage therapy requires informed phage selection and a comprehensive understanding of bacterial-phage-human host relationships and the management of bacterial and phage adaptations that occur in vivo. Phages may be used in ways that antibiotics are not and are a powerful approach for addressing the problem of antimicrobial resistance, not least because their optimal use requires a more thoughtful approach. In this Review, we explore key aspects of phage biology that underpin the effective use of phages for therapy. We outline clinical strategies for applying phages against a range of infections, highlighting their advantages and limitations. We then address challenges in production, scalability and regulation of phage preparations, identifying areas requiring further development. Finally, we discuss interactions between phages and the human immune system, and their importance for therapeutic success.
Identifiers
42661088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.